Journal of Clinical Virology
Volume 47, Issue 1 , Pages 69-71 , January 2010

Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: Rapid response to treatment with rituximab

  • Richa Uppal

      Affiliations

    • Department of Medicine, New York Downtown Hospital, NY, United States
    • ,
  • Edgar Charles

      Affiliations

    • Center for the Study of Hepatitis C, Weill Medical College of Cornell University and Rockefeller University, New York, NY, United States
    • ,
  • Gerond Lake-Bakaar

      Affiliations

    • Center for the Study of Hepatitis C, Weill Medical College of Cornell University and Rockefeller University, New York, NY, United States
    • Corresponding Author InformationCorresponding author. Present address: Liver Center, Suite 7A-055, Beth Israel Medical Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Boston, MA 02115, United States. Tel.: +1 617 632 9838; fax: +1 617 632 9840.

Received 21 July 2009 ,Revised 29 September 2009 ,Accepted 6 October 2009.

References 

  1. Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol. 1997;19(1):111–129
  2. Dammacco F, Sansonno D. Antibodies to hepatitis C virus in essential mixed cryoglobulinaemia. Clin Exp Immunol. 1992;87(March (3)):352–356
  3. Lidove O, Cacoub P, Maisonobe T, Servan J, Thibault V, Piette JC, et al. Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinaemia. Ann Rheum Dis. 2001;60(March (3)):290–292
  4. Lidove O, Maisonobe T, Servan J, Thibault V, Leger JM, Piette JC, et al. Peripheral neuropathy and hepatitis C virus infection: more than cryoglobulinemia. La Revue de medecine interne/fondee. 2001;22(October (10)):939–947
  5. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(February (2)):613–620
  6. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62(December (12)):1230–1233
  7. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?. Ann Rheum Dis. 2008;67(March (3)):283–287
  8. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74(April (4)):485–489
  9. Lake-Bakaar G, Dustin L, McKeating J, Newton K, Freeman V, Frost SD. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood. 2007;109(January (2)):845–846
  10. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003;101(June (10)):3818–3826
  11. Hardy RR. B-1 B cell development. J Immunol. 2006;177(September (5)):2749–2754
  12. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood. 2000;95(January (2)):627–632
  13. Bonetti B, Scardoni M, Monaco S, Rizzuto N, Scarpa A. Hepatitis C virus infection of peripheral nerves in type II cryoglobulinaemia. Virchows Arch. 1999;434(June (6)):533–535
  14. Itoh K, Tanaka H, Shiga J, Hirakawa K, Akahane Y, Tsuda F, et al. Hypocomplementemia associated with hepatitis C viremia in sera from voluntary blood donors. Am J Gastroenterol. 1994;89(November (11)):2019–2024
  15. Carson CW, Conn DL, Czaja AJ, Wright TL, Brecher ME. Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. J Rheumatol. 1993;20(February (2)):304–309
  16. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63(8):803–843
  17. Knapp MJ, Colburn PA. Clinical uses of intravenous immune globulin. Clin Pharm. 1990 Jul;9(7):509–529
  18. Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2007;122(February (2)):139–145
  19. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122(January (1)):62–74
  20. Linton PJ, Harbertson J, Bradley LM. A critical role for B cells in the development of memory CD4 cells. J Immunol. 2000;165(December (10)):5558–5565
  21. Lake-Bakaar G, Tsang P. Controlling B-cell activating factor (BAFF/BLyS) levels in chronic hepatitis C virus infection. DDW; 2008.

PII: S1386-6532(09)00496-X

doi: 10.1016/j.jcv.2009.10.006

Journal of Clinical Virology
Volume 47, Issue 1 , Pages 69-71 , January 2010

Article Tools